Investigating the role of Pluronic-g-Cationic polyelectrolyte as functional stabilizer for nanocrystals: Impact on Paclitaxel oral bioavailability and tumor growth

Sharma, Shweta; Verma, Ayushi; Pandey, Gitu; Mittapelly, Naresh; Mishra, Prabhat Ranjan

doi:10.1016/j.actbio.2015.08.005

Cited by 61 publications

(31 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[41,45] In addition, positively charged PTX nanoparticles showed higher cell endocytosis than those of negatively charged and neutral ones. [35,46,47] In conclusion, in this study, the preparation of PTX NCs via microfluidic approach using CMCS as nanocarrier improved the extent of cell endocytosis.…”

Section: In Vitro Assaysmentioning

confidence: 64%

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

et al. 2020

View full text Add to dashboard Cite

In the present study, the effectiveness of paclitaxel nanocrystals (PTX NCs) encapsulated in carboxymethyl chitosan (CMCS) nanoparticles (CMCS−PTX NPs) as an anticancer drug is evaluated. The CMCS nanoparticles are produced via a cross‐junction microfluidic device where the PTX/CMCS concentration and flow rates in the device are optimized. The dynamic light scattering data show that the PTX NCs have a median diameter size of 230±90 nm, while the size of CMCS−PTX NPs is roughly 270±30 nm. The zeta‐potential result indicates less negative surface charge for the CMCS−PTX NPs as compared to the PTX NCs. Moreover, scanning electron microscopy micrographs, differential scanning calorimetry thermograms, and X‐ray diffraction patterns reveal that the physicochemical properties of the drug remain unaltered after perfusion through the microfluidic device. Cytotoxicity and cell endocytosis of PTX NCs and CMCS−PTX NPs are evaluated in vitro using G361 melanoma‐positive skin cells. The results reveal that the CMCS−PTX NPs increase the cellular uptake and cytotoxicity compared to the PTX NCs alone. In addition, the antitumor effect of CMCS−PTX NPs on B16 melanoma indicates the great potential of CMCS as a promising nano‐carrier for PTX NCs drug with potent inhibitory effect on the tumor growth.

show abstract

Section: In Vitro Assaysmentioning

confidence: 64%

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As conveyed in our recent publication [25], in which we employed the same model chemotherapeutic drugs loaded within β -CM, various vehicles for oral administration of PTX have been investigated [44][45][46][47][48]. Moreover, recent studies examined the possibility of oral co-delivery of PTX along with a P-gp transport inhibitor [49,50].…”

Section: Discussionmentioning

confidence: 99%

Re-assembled Casein Micelles for Oral Delivery of Chemotherapeutic Combinations to Overcome Multidrug Resistance in Gastric Cancer

2018

J Mol Clin Med.

View full text Add to dashboard Cite

Multidrug resistance (MDR) mediated by ATP-dependent efflux transporters continues to be a dominant obstacle towards curative cancer therapy. We have previously demonstrated the ability of β-casein micelles (β-CM) to orally deliver a combination of individually encapsulated hydrophobic cargo of drugs and chemosensitizers designed to overcome MDR in gastric cancer. Herein we investigated the potential of reassembled casein micelles (rCM) to serve as a target-activated delivery platform comprising a synergistic duo of a chemotherapeutic drug (paclitaxel) and a P-glycoprotein-specific transport inhibitor (tariquidar). The high binding affinity of paclitaxel and tariquidar to rCM was demonstrated by spectrofluorometry. Furthermore, solubilization of the drugs and suppression of crystal growth was shown by light microscopy and dynamic light scattering. A remarkable antitumor activity and complete MDR reversal were demonstrated in the in vitro cytotoxicity assay against MDR human gastric carcinoma cells overexpressing P-glycoprotein. The structure and cytotoxic activity of drug-loaded rCM were completely retained after freeze-drying and reconstitution as in β-CM. Hence, our findings highlight the great potential of casein-based nanovehicles as efficient platforms for oral delivery and local target-activated release of synergistic hydrophobic drug combinations to treat gastric cancer, and overcome of cancer chemoresistance, and for the possible treatment of non-malignant gastric disorders.

show abstract

“…Nine‐fold increase in solubility was observed with NCs (7.3 ± 0.52 μg/mL) compared to coarse suspension (0.850 ± 0.12 μg/mL) (Figure (b)). Almost 12.6‐fold increased bioavailability was observed with PTX NCs than Taxol™ with much less clearance (Figure (c)) and PTX NC formulation was more efficacious in reducing the tumor growth compared to the Taxol™ due to the higher absorption and thus higher systemic levels of drug (Figure (d)) . Another example is silybin NCs A (SN‐A) and silybin NCs B (SN‐B), the particle size were 641.8 ± 14.7 nm (PDI ~ 0.375) and 127 ± 1.9 nm (PDI ~ 0.292), respectively, although both SN‐A and SN‐B displayed a nearly two to threefold improvement in bioavailability, SN‐B exhibited the highest C max and AUC (0‐∞) .…”

Section: Drug Ncs‐based Cancer Therapymentioning

confidence: 99%

Drug nanocrystals for cancer therapy

Miao

Yang

Feng

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Drug nanocrystals (NCs) with fascinating physicochemical properties have attracted great attention in drug delivery. High drug-loading efficiency, great structural stability, steady dissolution, and long circulation time are a few examples of these properties, which makes drug NCs an excellent formulation for efficient cancer therapy. In the last two decades, there are a lot of hydrophobic or lipophilic drugs, such as paclitaxel (PTX), camptothecin (CPT), thymectacin, busulfan, cyclosporin A, 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH), and so on, which have been formulated into drug NCs for cancer therapy. In this review, we summarized the recent advances in drug NCs-based cancer treatment. So far, there are main three methods to synthesize drug NCs, including top-down, bottom-up, and combination methods. The characterization methods of drug NCs were also elaborated. Furthermore, the applications and mechanisms of drug NCs were introduced by their administration routes. At the end, we gave a brief conclusion and discussed the future perspectives of drug NCs in cancer therapy. This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

show abstract

Investigating the role of Pluronic-g-Cationic polyelectrolyte as functional stabilizer for nanocrystals: Impact on Paclitaxel oral bioavailability and tumor growth

Cited by 61 publications

References 68 publications

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

Re-assembled Casein Micelles for Oral Delivery of Chemotherapeutic Combinations to Overcome Multidrug Resistance in Gastric Cancer

Drug nanocrystals for cancer therapy

Contact Info

Product

Resources

About